Roche Holding AG / Promedior, Inc.

Idiopathic Pulmonary Fibrosis (IPF)

35K US cases/yr

Disease Overview

Idiopathic pulmonary fibrosis is a chronic, progressive scarring of the lungs of unknown cause that destroys alveolar architecture, restricts oxygen exchange, and ultimately leads to respiratory failure. It primarily affects adults over 65 and carries a median survival of 3-5 years from diagnosis, with no curative therapy short of lung transplant.

Competitive Landscape

The IPF standard of care at the time of the Roche-Promedior deal was dominated by two anti-fibrotics: Roche's own Esbriet (pirfenidone), acquired via the 2014 InterMune buy, and Boehringer Ingelheim's Ofev (nintedanib). Both slow lung function decline but neither halts or reverses fibrosis, leaving substantial unmet need. Esbriet's orphan exclusivity was due to expire in 2021, exposing Roche to generic erosion and creating strategic urgency for a next-generation asset. Promedior's PRM-151 (zinpentraxin alfa), a recombinant human pentraxin-2 protein with FDA Breakthrough Therapy designation, demonstrated in Phase 2 statistically significant lung function preservation on top of standard of care plus improvement on the six-minute walk test. Roche framed the acquisition as a defensive-plus-offensive play: protect the IPF franchise post-Esbriet exclusivity loss, while expanding into a disease-modifying mechanism that could be paired with existing anti-fibrotics. Competing pipeline assets in 2019 included BMS's bexotegrast (then in earlier development) and Galapagos/Gilead's ziritaxestat. Roche planned to advance PRM-151 into Phase 3 in IPF by year-end 2019.

Myelofibrosis

Disease Overview

Myelofibrosis is a rare, chronic myeloproliferative neoplasm characterized by progressive bone marrow scarring, splenomegaly, cytopenias, and constitutional symptoms. It can arise de novo (primary MF) or evolve from polycythemia vera or essential thrombocythemia, and outcomes range widely with high-risk disease carrying poor median survival.

Competitive Landscape

At the time of the Roche-Promedior deal, the myelofibrosis market was dominated by Incyte's Jakafi (ruxolitinib), the first-approved JAK1/2 inhibitor (2011), with Celgene/BMS's Inrebic (fedratinib) approved August 2019 as a second-line JAK inhibitor option. JAK inhibitors reduce spleen volume and improve symptoms but do not modify the underlying bone marrow fibrosis or extend long-term survival meaningfully. PRM-151's pentraxin-2 mechanism is mechanistically differentiated, attacking the fibrotic process itself rather than JAK-driven proliferation, and Phase 2 data suggested potential to address the fibrotic component that JAK inhibitors leave untouched. Pipeline competition in 2019 included Sierra Oncology's momelotinib (later Ojjaara/GSK 2023) and CTI BioPharma's pacritinib (Vonjo, approved 2022). Roche's strategic angle was to leverage its hematology commercial footprint and pair PRM-151 with JAK inhibitors as combination therapy.